Login to Your Account

Palatin Partners With AstraZenca In $310M Obesity Program Deal

By Jennifer Boggs

Thursday, February 1, 2007
In its second major collaboration involving melanocortin receptors, Palatin Technologies Inc. signed a potential $310 million deal with AstraZeneca plc to develop small-molecule compounds for obesity and other metabolic disorders. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription